Abstract

BackgroundThe Neurological involvement is the most common extra-renal complication of Shiga toxin-producing E. coli-hemolytic uremic syndrome (HUS) or typical HUS. On brain magnetic resonance examination, main neurological signs encompass acute lesions of the basal ganglia and the white matter, which could usually regress after Eculizumab infusion. In contrast, peripheral nervous system (PNS) manifestations in typical HUS are very rare and, when occurring, they require a careful management of neurological sequelae and an intensive multidisciplinary neuro-rehabilitation program.Case presentationHere, we present two pediatric cases of severe and complicated typical HUS with PNS manifestations who required therapeutic treatment and an intensive multidisciplinary neuro-rehabilitation program.In both cases, PNS manifestations were followed by the recovery from typical HUS-related severe central neurological damage and manifested mainly with marked bilateral motor deficit and hyporeflexia/areflexia in the lower limbs. The peripheral polyneuropathy was treated with immunosuppressive therapy (methylprednisolone boluses, i.v. immunoglobulins, plasma exchange), followed by a prolonged intensive neuro-rehabilitation program. After 8 months of rehabilitation, both patients gained complete functional recovery.ConclusionsPNS manifestations during typical HUS are a rare event and potentially leading to severe disability. A timely clinical assessment is mandatory to set up a prompt therapeutic and rehabilitation program and to obtain a complete clinical and functional recovery.

Highlights

  • Conclusionsperipheral nervous system (PNS) manifestations during typical hemolytic uremic syndrome (HUS) are a rare event and potentially leading to severe disability

  • The Neurological involvement is the most common extra-renal complication of Shiga toxinproducing E. coli-hemolytic uremic syndrome (HUS) or typical HUS

  • The key role of the complement system dysregulation is well known in the atypical HUS, while rising evidence underlies its involvement in the pathogenesis of typical HUS [13], supporting the “off label” use of an anti-C5convertase monoclonal antibody (Eculizumab) for treating more severe forms of this disease [14,15,16,17]

Read more

Summary

Conclusions

PNS manifestations during typical HUS are a rare event and potentially leading to severe disability.

Background
Findings
Discussion and conclusion

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.